$338.22
+1.85
(+0.55%)β²
0.56%
Downside
Day's Volatility :1.18%
Upside
0.63%
38.32%
Downside
52 Weeks Volatility :39.35%
Upside
1.67%
Period | United Therapeutics Corporation | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 43.84% | 6.5% | 0.0% |
6 Months | 54.29% | 7.1% | 0.0% |
1 Year | 38.52% | 9.8% | 0.0% |
3 Years | 83.54% | 14.2% | -20.2% |
Market Capitalization | 14.9B |
Book Value | $120.76 |
Earnings Per Share (EPS) | 21.42 |
PE Ratio | 15.7 |
PEG Ratio | 7.8 |
Wall Street Target Price | 324.02 |
Profit Margin | 42.05% |
Operating Margin TTM | 52.58% |
Return On Assets TTM | 12.25% |
Return On Equity TTM | 20.08% |
Revenue TTM | 2.5B |
Revenue Per Share TTM | 53.18 |
Quarterly Revenue Growth YOY | 33.7% |
Gross Profit TTM | 1.8B |
EBITDA | 1.3B |
Diluted Eps TTM | 21.42 |
Quarterly Earnings Growth YOY | 0.27 |
EPS Estimate Current Year | 24.51 |
EPS Estimate Next Year | 26.82 |
EPS Estimate Current Quarter | 5.65 |
EPS Estimate Next Quarter | 6.09 |
What analysts predicted
Downside of 4.2%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 1.6B | β 5.65% |
Net Income | 589.2M | β 40.99% |
Net Profit Margin | 36.2% | β 11.98% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 1.4B | β 11.0% |
Net Income | -104.5M | β 117.74% |
Net Profit Margin | -7.21% | β 43.41% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 1.5B | β 2.38% |
Net Income | 514.8M | β 592.63% |
Net Profit Margin | 34.71% | β 41.92% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 1.7B | β 13.63% |
Net Income | 475.8M | β 7.58% |
Net Profit Margin | 28.23% | β 6.48% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 1.9B | β 14.88% |
Net Income | 727.3M | β 52.86% |
Net Profit Margin | 37.56% | β 9.33% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 2.3B | β 20.2% |
Net Income | 984.8M | β 35.4% |
Net Profit Margin | 42.31% | β 4.75% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 491.5M | β 4.75% |
Net Income | 132.1M | β 44.8% |
Net Profit Margin | 26.88% | β 19.5% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 506.9M | β 3.13% |
Net Income | 240.9M | β 82.36% |
Net Profit Margin | 47.52% | β 20.64% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 596.5M | β 17.68% |
Net Income | 259.2M | β 7.6% |
Net Profit Margin | 43.45% | β 4.07% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 609.4M | β 2.16% |
Net Income | 267.6M | β 3.24% |
Net Profit Margin | 43.91% | β 0.46% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 614.7M | β 0.87% |
Net Income | 217.1M | β 18.87% |
Net Profit Margin | 35.32% | β 8.59% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 677.7M | β 10.25% |
Net Income | 306.6M | β 41.23% |
Net Profit Margin | 45.24% | β 9.92% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 3.4B | β 18.11% |
Total Liabilities | 612.4M | β 21.24% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 3.9B | β 15.07% |
Total Liabilities | 1.1B | β 85.01% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 4.6B | β 17.93% |
Total Liabilities | 1.2B | β 7.66% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 5.2B | β 12.01% |
Total Liabilities | 1.2B | β 0.79% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 6.0B | β 16.94% |
Total Liabilities | 1.2B | β 3.11% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 7.2B | β 18.57% |
Total Liabilities | 1.2B | β 5.26% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 6.0B | β 4.55% |
Total Liabilities | 1.2B | β 2.33% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 6.3B | β 4.99% |
Total Liabilities | 1.2B | β 2.0% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 6.7B | β 5.28% |
Total Liabilities | 1.3B | β 3.88% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 7.0B | β 5.12% |
Total Liabilities | 1.3B | β 3.24% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 7.2B | β 2.04% |
Total Liabilities | 1.2B | β 9.86% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 6.5B | β 9.37% |
Total Liabilities | 1.2B | β 2.12% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 778.4M | β 64.15% |
Investing Cash Flow | -820.6M | β 1.8% |
Financing Cash Flow | 6.3M | β 85.45% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -206.6M | β 126.54% |
Investing Cash Flow | -335.4M | β 59.13% |
Financing Cash Flow | 611.2M | β 9601.59% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 755.7M | β 465.78% |
Investing Cash Flow | -738.5M | β 120.18% |
Financing Cash Flow | -16.9M | β 102.77% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 598.2M | β 20.84% |
Investing Cash Flow | -486.9M | β 34.07% |
Financing Cash Flow | 44.8M | β 365.09% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 802.5M | β 34.15% |
Investing Cash Flow | -811.5M | β 66.67% |
Financing Cash Flow | 75.4M | β 68.3% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 128.2M | β 50.43% |
Investing Cash Flow | -189.3M | β 101.38% |
Financing Cash Flow | 55.5M | β 692.86% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 374.8M | β 192.36% |
Investing Cash Flow | -221.1M | β 16.8% |
Financing Cash Flow | 48.6M | β 12.43% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 106.3M | β 71.64% |
Investing Cash Flow | -227.2M | β 2.76% |
Financing Cash Flow | 24.7M | β 49.18% |
Sell
Neutral
Buy
United Therapeutics Corporation is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() United Therapeutics Corporation | 5.46% | 54.29% | 38.52% | 83.54% | 89.16% |
![]() Moderna, Inc. | -1.67% | 18.26% | -0.21% | -64.15% | 752.69% |
![]() Regeneron Pharmaceuticals, Inc. | -0.46% | 13.21% | 45.59% | 84.19% | 244.2% |
![]() Novo Nordisk A/s | -11.0% | 18.31% | 61.56% | 186.46% | 423.59% |
![]() Vertex Pharmaceuticals Incorporated | 3.85% | 14.43% | 39.88% | 147.45% | 195.07% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() United Therapeutics Corporation | 15.7 | 15.7 | 7.8 | 24.51 | 0.2 | 0.12 | NA | 120.76 |
![]() Moderna, Inc. | 24.73 | NA | 0.0 | -7.19 | -0.38 | -0.16 | NA | 33.47 |
![]() Regeneron Pharmaceuticals, Inc. | 31.35 | 31.35 | 1.46 | 44.44 | 0.15 | 0.08 | NA | 250.15 |
![]() Novo Nordisk A/s | 44.28 | 44.28 | 2.36 | 3.43 | 1.0 | 0.25 | 0.01 | 22.18 |
![]() Vertex Pharmaceuticals Incorporated | 31.85 | 31.85 | 0.53 | 16.98 | 0.24 | 0.13 | NA | 71.8 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() United Therapeutics Corporation | Buy | $14.9B | 89.16% | 15.7 | 42.05% |
![]() Moderna, Inc. | Buy | $45.3B | 752.69% | 24.73 | -115.82% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $116.9B | 244.2% | 31.35 | 29.45% |
![]() Novo Nordisk A/s | Buy | $572.0B | 423.59% | 44.28 | 36.55% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $126.7B | 195.07% | 31.85 | 39.46% |
Insights on United Therapeutics Corporation
Revenue is up for the last 6 quarters, 491.5M β 677.7M (in $), with an average increase of 6.1% per quarter
Netprofit is up for the last 2 quarters, 217.1M β 306.6M (in $), with an average increase of 29.2% per quarter
In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 23.1%
In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 103.0%
BlackRock Inc
Vanguard Group Inc
Wellington Management Company LLP
venBio Select Advisor LLC
Renaissance Technologies Corp
State Street Corporation
united therapeutics corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions. we currently have five approved products on the market, and a long-term mission of providing an unlimited supply of transplantable organs for those who need them! our employees can be found collaborating across the united states, europe and asia. as a group, we are relentless in our pursuit of βmedicines for lifeβ and continue to research and develop treatments for cardiovascular and pulmonary diseases, pediatric cancers, and other orphan diseases. #weareunitherians
Organization | United Therapeutics Corporation |
Employees | 1168 |
CEO | Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D. |
Industry | Health Technology |
Cubesmart
$338.22
+0.55%
Iqvia Holdings Inc.
$338.22
+0.55%
Microsectors Travel 3x Inlev
$338.22
+0.55%
Jack Henry & Associates Inc.
$338.22
+0.55%
Packaging Corporation Of America
$338.22
+0.55%
Cognizant Technology Solutions Corp.
$338.22
+0.55%
Synopsys Inc.
$338.22
+0.55%
Targa Resources Corp.
$338.22
+0.55%
Parker-hannifin Corporation
$338.22
+0.55%